12 results about "Fatty acid biosynthesis" patented technology

This invention belongs to the field of biomedical technology, specifically relating to a compound extracted from *Acer buergerianum* (a type of shrub), its extraction method, and its application in the preparation of drugs for the prevention or treatment of non-alcoholic fatty liver disease. This invention is the first to obtain a natural compound with a novel structure from *Acer buergerianum*, and provides a method for its preparation. Activity studies were conducted, and experimental data show that the compound exhibits low cytotoxicity and no significant cytotoxicity to normal cells. It can inhibit the expression of fatty acid synthases ACC, ACLY, and FAS, thereby inhibiting de novo fatty acid synthesis in cells, suppressing lipid droplet accumulation, and reducing cellular lipid levels. This compound has broad application prospects in the preparation of drugs for the prevention or treatment of non-alcoholic fatty liver disease.

The invention discloses a difunctional alcohol dehydrogenase derived from Geobacillus thermodenitrifis, the difunctional alcohol dehydrogenase takes NAD < + > as a cofactor, can specifically catalyze a continuous oxidation reaction of omega-hydroxy fatty acid, and catalyzes the omega-hydroxy fatty acid to synthesize alpha, omega-binary fatty acid through single enzyme catalysis without an aldehyde intermediate. The alcohol dehydrogenase has dual catalytic functions of alcohol oxidation and aldehyde oxidation, the oxidation process from hydroxymethylene to carboxyl can be completed in one step, the reaction steps are simplified, accumulation and separation of intermediate aldehyde are avoided, the conversion efficiency is improved, and the alcohol dehydrogenase is alpha, omega-dibasic fatty acid and is a novel alcohol dehydrogenase. The invention provides a simple and efficient biocatalysis way for biosynthesis of dodecanedioic acid, especially dodecanedioic acid, and has important industrial application value.

The invention relates to Escherichia coli ML001, a specific bacteriophage thereof and an application of the Escherichia coli ML001 in preventing alcoholic liver diseases. The Escherichia coli strain ML001 and the specific bacteriophage thereof are preserved in China General Microbiological Culture Collection Center (CGMCC). Animal experiments prove that the bacteriophage can effectively reduce the level of glutamic-pyruvic transaminase and glutamic oxalacetic transaminase in the plasma of an alcoholic liver disease model mouse, which indicates that the bacteriophage has a definite liver protection function. The histopathologic examination further shows that after the phage is administered, the number of lipid droplets in the liver of the mouse is obviously reduced, and the liver lipid accumulation is effectively relieved. On the molecular mechanism level, the bacteriophage can down-regulate expression of fatty acid synthesis genes Srebf1 and Acly at the same time and inhibit a lipid synthesis pathway; meanwhile, the expression of a chemotactic factor Ccl6 is reduced, and the inflammatory response of the liver is relieved.

The present disclosure relates to an antiviral pharmaceutical composition including an estrogen-related receptor γ (ERRγ) inhibitor as an active ingredient. According to embodiments of the present disclosure, an antiviral pharmaceutical composition containing an ERRγ inhibitor as an active ingredient has antiviral effects. In particular, the antiviral pharmaceutical composition is effective in preventing or treating RNA virus infections. Specifically, the ERRγ inhibitor, especially an ERRγ inverse agonist, may exhibit broad-spectrum antiviral effects by inhibiting ERRγ activity in RNA virus-infected cells, thereby blocking fatty acid biosynthesis mediated by sterol regulatory element-binding protein 1c (SREBP1c).

The application provides application of a LuPDH-E1beta1 gene in regulating plant fatty acid synthesis, and after overexpression of the LuPDH-E1beta1 gene in plants, the amount of plant fatty acid synthesis can be increased. The application also provides application of the LuPDH-E1beta1 gene in regulating plant salt tolerance and drought resistance, and after overexpression of the LuPDH-E1beta1 gene in plants, the salt tolerance and drought resistance of a PDH-E1beta1 gene deletion plant can be increased. Through exploration of the function of the LuPDH-E1beta1 gene in plant seed oil metabolism and response to abiotic stress, the application of the LuPDH-E1beta1 gene in regulating plant fatty acid synthesis and salt tolerance and drought resistance is given, and a blank in the application of the LuPDH-E1beta1 gene in genetic engineering is filled.

This invention discloses a GhLACS4 gene that regulates the oil content of plant seeds and its applications, belonging to the field of molecular biology. The nucleotide sequence of the GhLACS4 gene is shown in SEQ ID NO.1, and the amino acid sequence of its encoded protein is shown in SEQ ID NO.2. This gene mainly participates in fatty acid synthesis and affects the accumulation of oil in seeds by converting free fatty acids 18:2 into 18:2-CoA, thus providing gene resources for breeding high-oil cotton.

The invention discloses application of EIF3H in treatment of liver cancer. Research finds that MASH and hepatic fibrosis can be relieved by down-regulating fatty acid de novo synthesis of EIF3H, and tumorigenesis in an HCC mouse model induced by DEN + HFHC and HDTI + HFHC is inhibited. In mechanism, EIF3H is combined with FASN, and KEAP1 mediated FASN ubiquitination is antagonized, so that the FASN protein is stabilized. Therefore, EIF3H is a FASN deubiquitinase which is not illuminated previously, and drives the MASLD-HCC process by promoting fatty acid metabolism reprogramming. The EIF3H-FASN axis can be used as a therapeutic target of liver cancer.

Method and compositions for treating glioblastoma (GBM) and other cancers is disclosed, involving the combination of radiation therapy (RT), fatty acid synthase (FASN) inhibitors, and programmed cell death protein 1 (PD-1) inhibitors or programmed death ligand 1 (PD-L1) inhibitors. The disclosed approach addresses the technical problem of RT-induced immunosuppression and resistance in cancers by targeting RT-induced lipid metabolism, which promotes immune escape. FASN inhibitors block fatty acid synthesis, enhancing immune cell infiltration and restoring anti-tumor immunity. PD-1 / PD-L1 inhibitors further counteract immunosuppressive pathways to improve therapeutic efficacy. This combination therapy prolongs survival, induces immune memory, and is applicable to other cancers, including those exhibiting increased lipid content post-RT or chemotherapy, including melanoma, breast cancer, and lung cancer.

Therapeutic combinations of fatty acid synthesis modulators and thyroid hormone receptor agonists are provided. The combinations may be used to treat disorders including metabolic disorders and liver disorders, such as nonalcoholic steatohepatitis / metabolic dysfunction-associated steatohepatitis (NASH / MASH).

Therapeutic combinations of a fatty acid synthesis modulator and a thyroid hormone receptor agonist are provided. The combinations are useful in the treatment of conditions, including metabolic conditions and liver conditions, such as non-alcoholic steatohepatitis / metabolic dysfunction associated steatohepatitis (NASH / MASH).

Methods of treating NASH / MASH comprising administering a fatty acid synthesis (FASN) inhibitor and compositions for treating the same are provided herein.

The application discloses modified potato resistant starch and application thereof in set yogurt, and comprises the following steps: adding chitosan oligosaccharide and zinc salt into potato PRS3 starch milk, mixing and treating, reacting with leucine-glycine dipeptide to obtain composite modified potato PRS3 starch; pre-gelatinizing the composite modified potato PRS3 starch, mixing with milk, mixing, homogenizing, sterilizing, inoculating and fermenting, and post-ripening to prepare set yogurt. 2+ The chitosan oligosaccharide-Zn 2+ and leucine-glycine dipeptide composite modified potato PRS3 starch forms a reversible three-dimensional coordination network and hydrophobic interaction, significantly improves transparency, freeze-thaw stability and resistance retention rate, and enhances the adsorption and combination capacity of milk protein and milk fat. The set yogurt has good gel strength, texture characteristics and sensory quality, effectively promotes the proliferation of probiotics, improves the coagulation efficiency, prevents whey separation and promotes the synthesis of intestinal short-chain fatty acids, and improves intestinal health.